A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL

Liselotte Boeve; Maarten Hulshof; Andre Vis; Koos Zwinderman; Jos Twisk; Karl Delaere; Jeroen van Moorselaar; Paul Verhagen; George van Andel

A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL

Liselotte Boeve, Maarten Hulshof, Andre Vis, Koos Zwinderman, Jos Twisk, Karl Delaere, Jeroen van Moorselaar, Paul Verhagen, George van Andel

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	E231-E232
Journal	Journal of urology
Volume	199
Issue number	4
Publication status	Published - Apr 2018

Cite this

Boeve, L., Hulshof, M., Vis, A., Zwinderman, K., Twisk, J., Delaere, K., van Moorselaar, J., Verhagen, P., & van Andel, G. (2018). A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL. Journal of urology, 199(4), E231-E232.

Boeve, Liselotte ; Hulshof, Maarten ; Vis, Andre et al. / A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL. In: Journal of urology. 2018 ; Vol. 199, No. 4. pp. E231-E232.

@article{a4631645c32942898398c4015e66feb6,

title = "A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL",

author = "Liselotte Boeve and Maarten Hulshof and Andre Vis and Koos Zwinderman and Jos Twisk and Karl Delaere and {van Moorselaar}, Jeroen and Paul Verhagen and {van Andel}, George",

year = "2018",

month = apr,

language = "English",

volume = "199",

pages = "E231--E232",

journal = "Journal of urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "4",

}

Boeve, L, Hulshof, M, Vis, A, Zwinderman, K, Twisk, J, Delaere, K, van Moorselaar, J, Verhagen, P & van Andel, G 2018, 'A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL', Journal of urology, vol. 199, no. 4, pp. E231-E232.

A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL. / Boeve, Liselotte; Hulshof, Maarten; Vis, Andre et al.
In: Journal of urology, Vol. 199, No. 4, 04.2018, p. E231-E232.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL

AU - Boeve, Liselotte

AU - Hulshof, Maarten

AU - Vis, Andre

AU - Zwinderman, Koos

AU - Twisk, Jos

AU - Delaere, Karl

AU - van Moorselaar, Jeroen

AU - Verhagen, Paul

AU - van Andel, George

PY - 2018/4

Y1 - 2018/4

M3 - Meeting Abstract

SN - 0022-5347

VL - 199

SP - E231-E232

JO - Journal of urology

JF - Journal of urology

IS - 4

ER -

Boeve L, Hulshof M, Vis A, Zwinderman K, Twisk J, Delaere K et al. A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, FINAL DATA FROM THE HORRAD TRIAL. Journal of urology. 2018 Apr;199(4):E231-E232.